Wird geladen...
Second- and third-generation ALK inhibitors for non-small cell lung cancer
Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), w...
Gespeichert in:
| Veröffentlicht in: | J Hematol Oncol |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4782349/ https://ncbi.nlm.nih.gov/pubmed/26951079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0251-8 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|